Achieve Life Sciences shares drop as analysts see delayed launch of smoking-cessation treatmentMarket Watch • 12/12/23
Achieve Life Sciences to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 9, 2023GlobeNewsWire • 10/26/23
Achieve Life Sciences Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual MeetingGlobeNewsWire • 09/11/23
Achieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate UpdateGlobeNewsWire • 08/14/23
Achieve Life Sciences to Announce Second Quarter 2023 Financial Results and Host Conference Call and WebcastGlobeNewsWire • 08/01/23
Achieve Life Sciences Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association (JAMA)GlobeNewsWire • 07/11/23
Achieve Life Sciences says confirmatory late-stage trial of its treatment for quitting smoking achieved positive resultsMarket Watch • 05/23/23
Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical TrialGlobeNewsWire • 05/23/23
Achieve Life Sciences Announces Refinancing of Outstanding Loan with Silicon Valley BankGlobeNewsWire • 05/17/23
Achieve Life Sciences Reports Financial Results for First Quarter 2023 and Provides Corporate UpdateGlobeNewsWire • 05/09/23
Achieve Life Sciences to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 9, 2023GlobeNewsWire • 04/26/23
Achieve Life Sciences to Present at Life Science Innovation Northwest 2023 ConferenceGlobeNewsWire • 04/14/23
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2022 and Provides Corporate UpdateGlobeNewsWire • 03/16/23
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette CessationGlobeNewsWire • 03/08/23
Achieve Life Sciences Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco (SRNT) Annual MeetingGlobeNewsWire • 03/03/23
Achieve Life Sciences Announces Patent Granted by USPTO for New Cytisinicline FormulationGlobeNewsWire • 12/21/22